NewsBenzingaLeerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59 Leerink Partners Downgrades Bristol-Myers Squibb to Market Perform, Lowers Price Target to $59 Benzinga 2026.10.05 13:04 (GMT+0) Open on Benzinga Other news Keybanc Downgrades BILL Holdings to Sector Weight William Blair Upgrades Pyxis Oncology to Outperform BTIG Reiterates Buy on Walmart, Maintains $140 Price Target Procter & Gamble Plans up to 30% Supply Job Cuts by 2030, Aims for $10 Billion in Cost Savings Mark Cuban Says Healthcare Economics Run On ‘Contractual Terrorism’: ‘Even the Biggest Companies Get Ripped Off’ Hewlett Packard Enterprise Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call
Mark Cuban Says Healthcare Economics Run On ‘Contractual Terrorism’: ‘Even the Biggest Companies Get Ripped Off’
Hewlett Packard Enterprise Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call